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Adult T-cell leukemia/lymphoma (ATLL) is an aggressive type of leukemia/lymphoma associated with the human T-cell lymphotropic virus type 1 (HTLV-1) that is characterized by a short survival time and a poor response to chemotherapy \[[@B1]\]. There are several clinical subtypes of ATLL, namely an acute, lymphomatous, chronic, smoldering, and a rare cutaneous type \[[@B2], [@B3]\]. The disease is most frequently associated with a mature CD4+ CD8- T-cell phenotype. However, rare cases of an unusual form of immunophenotype characterized by co-expression of CD4+ CD8+ double-positive cells have been reported \[[@B4], [@B5], [@B6], [@B7]\]. Isolated case reports have suggested a median survival time of about 6--8 months despite intensive treatment. Characteristic clinical features include high white-cell counts, skin lesions, hepatosplenomegaly, lymphadenopathy and hypercalcemia. Here, we report a rare case of dual CD4+ CD8+ double-positive ATLL with complex cytogenetic characteristics and discuss the clinical presentation and the course of this rare disease.

Case Report {#sec1_2}
===========

A 43-year-old Caribbean male presented with a 3-day history of generalized body aches, weakness, myalgia, visual disturbances, dysphagia, constipation, and numbness in both feet. His past medical history was significant for hypertension and childhood infection of strongyloidiasis. Physical examination disclosed significant lethargy, malaise, uveitis in both eyes and, interestingly, right facial palsy. Routine laboratory test revealed a white blood cell count of 7,300/mm^3^, hemoglobin 10.4 mg/dl, hematocrit 31.3%, platelet 477,000/mm^3^, absolute neutrophil count 2,560 L, lymphocytes 5,500/mm^3^, serum calcium 15.6 mg/dl, serum albumin 3.9 g/dl, blood urea nitrogen 26 mg/dl, and serum creatinine 2.1 mg/dl. Other laboratory tests, including liver function tests, urine analysis, parathyroid hormone (PTH), parathyroid hormone related peptide (PTHrp), vitamin D3, angiotensin converting enzyme, serum protein electrophoresis, urine protein electrophoresis, serum immunoglobulins and immunofixation were within normal limits. Neuroimaging was unremarkable. Examination of peripheral smear revealed presence of abnormal lymphocytes with multilobulated clover-shaped nuclei. Computed tomography scans of the abdomen and pelvis showed a multifocal mass and enlargement of the liver and spleen. No enlargement of the periaortic, iliac or inguinal lymph nodes was observed. Serum antibodies against HTLV-1 (gp19, gp21) were found to be positive and negative for HIV. Bone marrow flow cytometric analysis also revealed 49% abnormal clones of T cells positive for CD2, CD4, CD5, CD8, CD25, CD38 and CD45 and non-immunoreactive for CD7, CD20, CD34, CD56, CD117, HLA-DR and terminal deoxynucleotidyl transferase. Cerebral spinal fluid flow cytometry confirmed similar findings with presence of clonal T cells positive for CD2, CD3, CD4, CD5, CD8 and CD25 and negative for CD7. Bone marrow cytogenic study showed a complex male karyotype of 47,XY with several numeric and structural abnormalities involving the long arm of chromosomes 1, 3, 6, 7, 12, 13, and 14q32, as well as the short arm of chromosomes 10, 17, and 21. We also noticed monosomy of chromosome 12 and unbalanced translocation on the long arm of chromosomes 5 and 13, additional material on the long arm of chromosomes 5, 7, 12, 14 (14q+ chromosome) and 17, and on the short arm of 2 of the 3 copies of chromosome 4 as well as a marker chromosome in 16 of 20 metaphases, suggesting a partial trisomy or inactive genetic material. Finally, rearrangement of the T-cell receptor γ (TCRγ) gene located on chromosome 7 was tested to analyze the clonality in T-cell lymphoproliferations amplified by fluorescent polymerase chain reaction (PCR), which showed a distinct band of the TCRγ gene, revealing T-cell clonal integration of proviral DNA of HTLV-1, thus confirming the diagnosis of acute ATLL.

The patient was given a chemotherapy regimen of etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone (EPOCH) along with aggressive management of hypercalcemia using hydration, bisphosphonates and calcitonin. Repeated flow cytometry after the 3rd cycle of the EPOCH regimen showed no abnormal phenotype in the bone marrow. However, after the 5th cycle of the EPOCH regimen, an Ommaya tap was done that revealed *Candida* species. The patient then underwent successful autologous stem cell transplantation with high-dose BEAM. Repeated bone marrow aspirate and biopsy 9 months after transplantation demonstrated no evidence of lymphoma and T-cell band, T-cell γ and T-cell σ, nor an abnormal phenotype on flow cytometry. However, after 13 months of autologous stem cell transplantation, the patient relapsed and was admitted to the hospital with refractory hypercalcemia. Salvage regimen which included gemcitabine and vinorelbine was started. Unfortunately, the response to the treatment was poor and a hyper-CVAD regimen (i.e., a high dose of methotrexate and a high dose of cytarabine) was introduced with rapid resolution of hypercalcemia and white cell count. However, disease recurred again with refractory hypercalcemia after 3 months, being complicated by disseminated infection requiring antibacterial, antiviral and antifungal agents. Overall, the patient survived for 25 months from the time of diagnosis and 17 months after transplantation.

Discussion {#sec1_3}
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We have reported a rare case of expansion of a CD4+ CD8+ double-positive cell population in a Caribbean male with a complex male karyotype, infected with HTLV-1. The disease was first described in Kyushu, in southwestern Japan, and it occurs most frequently in endemic areas such as Japan, the Caribbean basin, West Africa, Brazil, Central and South America and northern Iran \[[@B2], [@B4]\]. The disease is considered a fatal malignant post-thymic lymphoproliferative disorder and is characterized by the presence of leukemic cells with highly convoluted nuclei (so-called \'flower-like cells\'), lymphadenopathy, hepatosplenomegaly, skin lesions, and hypercalcemia.

The involvement of CD4+ cells in the development of ATLL is indisputable; however, few case reports have noticed an unusual phenotype of double-positive CD4+ and CD8+ expression in patients with an extremely aggressive course.

Kim et al. \[[@B8]\] reported an extremely aggressive course with poor survival in a patient with CD4+ CD8+ double-positive acute adult T-cell leukemia with skin manifestations. Kamihira et al. \[[@B7]\] reported a poorer prognosis with a median survival of 7.8 months as compared to patients with the typical CD4- CD8- phenotype. Ciminale et al. \[[@B9]\] describe a CD4+ CD8+ phenotype acute lymphoma in a Greek patient with an aggressive clinical course of refractory hypercalcemia. Several authors have implicated a high proliferation index (\>18%), and large cells are suggestive of a poor prognosis in these patients \[[@B10]\].

Although HTLV-1 infects both CD4+ and CD8+ T cells, leukemogenic potential of the virus is restricted to the CD4+ subset. The dynamic relationship between the co-expansion of two cell populations of CD4+ and CD8+ in the course of the disease is still unclear. However, since the CD4/CD8 double-positive phenotype is characteristically associated with the majority of immature thymic precursors, it is hypothesized that the infection with HTLV-1 and expansion of CD8+ cells plays a helper role in the selection of specific CD4+ cell clones, and thus, during intrathymic ontogeny, immature CD4+/CD8+ thymocytes develop into functionally competent CD3+/CD4+/CD8- or CD3+/CD4-/CD8+ T cells after transient expression of the CD4/CD8 double-positive phenotype \[[@B11]\]. Sibon et al. \[[@B12]\] have shown that infected CD4+ and CD8+ cells displayed the same pattern of clonal expansion in vivo, and both subsets of T cells disseminated the virus at a proviral state, although the degree of clonal expansion was higher in CD4+ than in CD8+ lymphocytes, which accounted for the significantly higher proviral loads harbored by the CD4+ subset of T cells. Alternatively, the viral infection may alter the expression of interleukin-4, which can modulate the expression of CD8 on the surface of CD4+ T cells, resulting in a concomitant expression of both markers \[[@B13]\].

Another possible mechanism includes clonal expansion of a less differentiated cell population which is immortalized by HTLV-1 infection; however, the finding that terminal deoxynucleotidyl transferase, which is a marker for thymic T-cell precursors, is usually not expressed in the infiltrative tumor cells opposes this hypothesis \[[@B7], [@B11], [@B12], [@B13]\].

One of the distinct features of the disease is refractory hypercalcemia, which requires frequent hospitalization and aggressive hydration. This phenomenon has been studied previously by Prager et al. \[[@B14]\] and other study groups \[[@B15], [@B16], [@B17], [@B18], [@B19]\]. They have shown increased bone resorption mediated by parathyroid hormone-related protein (PTHrP), transactivated by the HTLV-1 tax and HTLV-11 tax proteins, which mediates its effects on PTHrP via cellular transcription factors activator protein (AP)-2 and AP-1. Transactivation via an AP-2 motif represents a novel interaction of tax with a cellular transcription factor or lymphokines such as interleukin 1 (IL-1), IL-2, IL-6 and tumor necrosis factor (TNF), and dysregulation of cellular gene transcription by viral proteins. Interestingly, the hypercalcemia in our patient occurred in the setting of normal PTHrP and low 1,25(OH)~2~D levels, supporting the role for cytokines in the development of HTLV-1-related hypercalcemia \[[@B20]\].

Another interesting feature are the clonal chromosome abnormalities along with clinical heterogeneity and a plethora of secondary abnormalities in our patient. Interestingly, we noticed a hyperdiploid male karyotype, monosomy of chromosome 12 and an unbalanced translocation on the long arm of chromosomes 5 and 13, additional material on the long arm of chromosomes 5, 7, 12, 14 (14q+ chromosome) and 17 and on the short arm of 2 of the 3 copies of chromosome 4, and a marker chromosome in 16 of 20 metaphases, suggesting a partial trisomy or inactive genetic material. Five of these metaphases also showed a second copy of the marker chromosome. Interestingly, only 4 metaphases showed a normal karyotype. Complex cytogenetic characteristics are presented in fig. [1](#F1){ref-type="fig"}.

Itoyama et al. \[[@B21]\] reveal cytogenetic findings in 50 cases of ATLL where multiple breaks (at least 6), abnormalities of chromosomes 1p, 1p22, 1q, 1q10-21, 2q, 3q, 3q10-12, 3q21, 14q, 14q32 and 17q, and partial loss of chromosomes 2q, 9p, 14p, 14q and 17q regions correlated with shorter survival \[[@B19]\]. The most frequent gains include trisomy 3, trisomy 8, trisomy 9 and trisomy 21. Monosomies involve chromosomes 4, 8, 10 and 22.

Several authors have also suggested that 14q32 translocations were the most common abnormalities and are consistently observed in human T-cell tumors \[[@B22], [@B23]\]. To date, this is the only report which showed monosomy of chromosome 12 and complex cytogenetic chromosomal abnormalities with a male karyotype in HTLV-1 CD4+ CD8+ double-positive lymphoma.

We believe that despite the aggressive course of the disease, the current treatment has allowed the patient to live longer. We used EPOCH chemotherapy with a 4-day infusion schedule of cyclophosphamide, vincristine, doxorubicin and etoposide, followed by antiretroviral therapy and successful autologous bone marrow transplantation with BEAM therapy. The patient remained in complete remission for 13 months after bone marrow transplantation with no evidence of recurrent HTLV-1 infection on PCR testing and on flow cytometry. However, salvage regimen which included gemcitabine and vinorelbine and, later on, hyper-cyclophosphamide, vincristine, adriamycin and dexamethasone resulted in a transient response after relapse.

In conclusion, we have shown that double-positive ATLL is an aggressive form of lymphoma associated with refractory hypercalcemia. Despite recent advances in treatment, information about this rare disease is still limited. In connection with the multiple chromosomal aberrations and complex cytogenetic characteristics observed in our patient, further investigation into the role of HTLV-1 in these lymphomas and clinical trials are warranted.
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